Centene (CNC) Receives a Hold from Guggenheim

Guggenheim analyst Jason Cassorla maintained a Hold rating on Centene yesterday. The company’s shares closed yesterday at $38.04.

Valentine's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Cassorla covers the Healthcare sector, focusing on stocks such as Cigna, Centene, and Tenet Healthcare. According to TipRanks, Cassorla has an average return of -5.7% and a 42.55% success rate on recommended stocks.

Currently, the analyst consensus on Centene is a Hold with an average price target of $43.44, implying a 14.20% upside from current levels. In a report released on February 8, Cantor Fitzgerald also maintained a Hold rating on the stock with a $41.00 price target.

Based on Centene’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $49.73 billion and a GAAP net loss of $1.1 billion. In comparison, last year the company earned a revenue of $40.81 billion and had a net profit of $283 million

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CNC in relation to earlier this year. Most recently, in December 2025, Kenneth Burdick, a Director at CNC sold 66,007.00 shares for a total of $2,575,601.44.